Moleculin Biotech is trading at $0.47, up 5.25% in pre-market on October 7, 2026; available coverage identifies no company-specific catalyst. - Shares closed at $0.45 on October 6. - The latest reported company announcement was September 29, when it completed enrollment in Part A of its MIRACLE trial; that news does not establish the cause of this morning’s gain. - The broader market backdrop is mixed, and available information does not identify pre-market trading volume.